Ardsley Advisory Partners LP Buys 9,000 Shares of argenex SE $ARGX

Ardsley Advisory Partners LP boosted its stake in argenex SE (NASDAQ:ARGX) by 60.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,000 shares of the company’s stock after buying an additional 9,000 shares during the quarter. argenex makes up about 2.2% of Ardsley Advisory Partners LP’s investment portfolio, making the stock its 7th largest position. Ardsley Advisory Partners LP’s holdings in argenex were worth $20,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of ARGX. AQR Capital Management LLC boosted its stake in argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC lifted its stake in argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after buying an additional 1,431 shares during the period. Focus Partners Wealth lifted its stake in argenex by 22.3% in the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after buying an additional 73 shares during the period. Geneos Wealth Management Inc. lifted its stake in argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of argenex by 60.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analysts Set New Price Targets

ARGX has been the topic of a number of research analyst reports. Robert W. Baird raised their price target on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. HC Wainwright raised their price target on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Royal Bank Of Canada decreased their price target on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Wells Fargo & Company lifted their target price on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Price Performance

Shares of NASDAQ ARGX opened at $892.26 on Thursday. The stock has a market capitalization of $55.49 billion, a PE ratio of 39.73, a P/E/G ratio of 1.34 and a beta of 0.47. The business has a fifty day moving average price of $820.36 and a two-hundred day moving average price of $810.81. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion during the quarter. On average, equities analysts expect that argenex SE will post 26.19 EPS for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.